These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21492126)

  • 1. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
    Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
    Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
    Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
    Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
    Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
    McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
    Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Okumura K; Sinicrope FA
    Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
    Martin AP; Mitchell C; Rahmani M; Nephew KP; Grant S; Dent P
    Cancer Biol Ther; 2009 Nov; 8(21):2084-96. PubMed ID: 19823038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy.
    Heidari N; Hicks MA; Harada H
    Cell Death Dis; 2010 Sep; 1(9):e76. PubMed ID: 21364679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization.
    Stamelos VA; Fisher N; Bamrah H; Voisey C; Price JC; Farrell WE; Redman CW; Richardson A
    PLoS One; 2016; 11(3):e0150696. PubMed ID: 26950068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
    Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
    Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells.
    Yu L; Wu WK; Gu C; Zhong D; Zhao X; Kong Y; Lin Q; Chan MT; Zhou Z; Liu S
    Oncotarget; 2016 Mar; 7(12):14693-707. PubMed ID: 26910910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.